Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Does Menopausal Hormone Therapy Reduce Fracture Risk?

J Clin Endocrinol Metab; ePub 2017 Mar 6; Wang, et al

Fracture risk is reduced in postmenopausal women who initiate hormone therapy (HT), especially in those at greatest genetic risk of fracture and low bone mineral density (BMD), a recent study found. The study included 9,922 genotyped white postmenopausal women aged 50 to 79 years from the Women’s Health Initiative HT randomized trials and 40 US clinical centers. 2 weighted genetic risk scores (GRSs) were developed based on 16 fracture-associated variants (Fx-GRS) and 50 BMD variants (BMD-GRS). Researchers found:

  • Both GRSs were associated with fracture risk (HR per 1-unit increment in GRS, 1.04 for FX-GRS and 1.03 for BMD-GRS).
  • There was no evidence for multiplicative interaction for either of the GRSs.
  • There was however, a significant additive interaction, where the highest quartile of both GRSs and randomization to placebo have excess fracture risk.

Citation:

Wang Y, Wactawski-Wende J, Sucheston-Campbell LE, et al. Gene-hormone therapy interaction and fracture risk in postmenopausal women. [Published online ahead of print March 6, 2017]. J Clin Endocrinol Metab. doi:10.1210/jc.2016-2936.